Everest Medicines Acquires Exclusive Rights to Novel Biologic for Eye Disorders
Everest Medicines has acquired an exclusive license to develop and commercialize VIS-101, a novel bifunctional biologic for serious eye disorders, in Greater China and other Asian countries.
Partnership Details
The license was acquired from Visara, Inc., a subsidiary of NovaBridge Biosciences, listed on the Nasdaq Global Market. The agreement covers Greater China, Singapore, South Korea, and certain Southeast Asian countries.
- Upfront payment: US$7 million (approximately RMB49.7 million)
- Reimbursement for prior expenses: up to RMB24.0 million
- Potential future payments: up to US$89 million
No direct quote available in the given text.
This collaboration marks Everest's expansion into ophthalmology, enriching its late-stage product pipeline and strengthening its core therapeutic portfolio.
Author's summary: Everest Medicines expands into ophthalmology with VIS-101 license.
More News
- 2025 NBA Cup TRACKER: Scores, Schedule, Standings
- Idaho State History Museum offers free admission to veterans on Veterans Day
- NewJeans to Appeal Label Contract Court Decision
- Idaho Farm Bureau Takes Agricultural Education on the Road
- The Week in AgriFoodTech: Fork & Good acquires Orbillion Bio, $100m regen ag fund, Beyond Meat in court
- Dean Lewis Shares Statement Following Misconduct Allegations
- Humphrey School Students Host First-Ever Minneapolis Mayoral Forum
- Stranger Things 5 trailer shows way more than we were ready for
- Kerala Blasters pip Rajasthan Utd 1-0The Shillong Times
- Billie Eilish Calls on Billionaires to Do More for People in Need